Literature DB >> 9950442

Differences between asthma exacerbations and poor asthma control.

H Reddel1, S Ware, G Marks, C Salome, C Jenkins, A Woolcock.   

Abstract

BACKGROUND: Increased variation in peak expiratory flow (PEF) is characteristic of poorly controlled asthma, and measurement of diurnal variability of PEF has been recommended for assessment of asthma severity, including during exacerbations. We aimed to test whether asthma exacerbations had the same PEF characteristics as poor asthma control.
METHODS: Electronic PEF records from 43 patients with initially poorly controlled asthma were examined for all exacerbations that occurred after PEF reached a plateau with inhaled corticosteroid treatment. Diurnal variability of PEF was compared during exacerbations, run-in (poor asthma control), and the period of stable asthma before each exacerbation.
FINDINGS: Diurnal variability was 21.3% during poor asthma control and improved to 5.3% (stable asthma) with inhaled corticosteroid treatment. 40 exacerbations occurred in 26 patients over 2-16 months; 38 (95%) of exacerbations were associated with symptoms of clinical respiratory infection. During exacerbations, consecutive PEF values fell linearly over several days then improved linearly. However, diurnal variability during exacerbations (7.7%) was not significantly higher than during stable asthma (5.4%, p=0.1). PEF data were consistent with impaired response to inhaled beta2-agonist during exacerbations but not during poorly controlled asthma.
INTERPRETATION: Asthmatics remain vulnerable to exacerbations during clinical respiratory infections, even after asthma is brought under control. Calculation of diurnal variability may fail to detect important changes in lung function. PEF variation is strikingly different during exacerbations compared with poor asthma control, suggesting differences in beta2-adrenoceptor function between these conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950442     DOI: 10.1016/S0140-6736(98)06128-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Diurnal variability--time to change asthma guidelines?

Authors:  H Reddel; C Jenkins; A Woolcock
Journal:  BMJ       Date:  1999-07-03

Review 2.  Oral corticosteroids for exacerbations of chronic obstructive pulmonary disease.

Authors:  J A Wedzicha
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Outcome measures in asthma.

Authors:  N C Barnes
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 4.  Low dose inhaled corticosteroids and the prevention of death from asthma.

Authors:  J C Kips; R A Pauwels
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

5.  Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations.

Authors:  J M FitzGerald; A Becker; M R Sears; S Mink; K Chung; J Lee
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

Review 6.  Management of severe asthma in children.

Authors:  Andrew Bush; Sejal Saglani
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

7.  Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program.

Authors:  Anne M Fitzpatrick; W Gerald Teague; Deborah A Meyers; Stephen P Peters; Xingnan Li; Huashi Li; Sally E Wenzel; Shean Aujla; Mario Castro; Leonard B Bacharier; Benjamin M Gaston; Eugene R Bleecker; Wendy C Moore
Journal:  J Allergy Clin Immunol       Date:  2010-12-31       Impact factor: 10.793

8.  Exacerbation-Prone Asthma.

Authors:  Loren C Denlinger; Peter Heymann; Rene Lutter; James E Gern
Journal:  J Allergy Clin Immunol Pract       Date:  2019-11-22

9.  When can personal best peak flow be determined for asthma action plans?

Authors:  H K Reddel; G B Marks; C R Jenkins
Journal:  Thorax       Date:  2004-11       Impact factor: 9.139

Review 10.  Asthma exacerbations . 4: Prevention.

Authors:  J M FitzGerald; P G Gibson
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.